Results 81 to 90 of about 1,727,618 (310)
medRxiv, 2020 The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans.
A. Addetia +8 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop +10 more
wiley +1 more source
In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.
PLoS ONE, 2011 BackgroundThe rapid and continual viral escape from neutralizing antibodies is well documented in HIV-1 infection. Here we report in vivo emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling the development ...
Marlén M I Aasa-Chapman +7 more
doaj +1 more source
Neutralization of HIV-1 by antibody
Current Opinion in Immunology, 1996 The humoral immune response to HIV-1 has been extensively studied over the past few years and considerable advances have been made in understanding the dynamics and specificity of the neutralizing antibody component during and after seroconversion. Despite this, there is still no clear understanding of the role of neutralizing antibodies in controlling
openaire +3 more sources
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies [PDF]
BMC Systems Biology, 2011 Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, and its role in cancer biology has been widely studied. Many cancer therapies target angiogenesis, with a focus being on VEGF-mediated signaling such as antibodies to VEGF. However, it is difficult to predict the effects of VEGF-neutralizing agents.
P. I. Imoukhuede +3 more
openaire +3 more sources
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
bioRxiv, 2020 The pandemic caused by emerging coronavirus SARS-CoV-2 presents a serious global public health emergency in urgent need of prophylactic and therapeutic interventions.
B. Ju +21 more
semanticscholar +1 more source
Broadly Neutralizing Antibodies for HIV Eradication [PDF]
Current HIV/AIDS Reports, 2016 Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent ...
Kathryn E. Stephenson +3 more
openaire +4 more sources
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian +10 more
wiley +1 more source
Scientific Reports, 2022 Oncolytic adenoviruses (OAds), most of which are based on species C human adenovirus serotype 5 (Ad5) (OAd5), have recently received much attention as potential anticancer agents.
Ryosuke Ono +4 more
doaj +1 more source